Personalized Comorbidity-Integrated Gout Care

个性化合并症综合痛风护理

• 批准号: 10663477
• 负责人: Chio Yokose
• 金额: $ 17.6万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-01 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10663477
• 关键词: Address; Adherence; Affect; Agonist; Angiotensin-Converting Enzyme Inhibitors; Area; Biological Markers; Biology; Calcium Channel Blockers; Caring; Chronic Kidney Failure; Clinic; Clinical; Clinical effectiveness; Comparative Effectiveness Research; Data; Development; Diabetes Mellitus; Diagnosis; Doctor of Philosophy; East Asian; Electronic Health Record; Emergency department visit; Enrollment; Environment; Epidemiology; Evolution; Exhibits; Faculty; Fellowship; Flare; Funding; GLP-I receptor; General Hospitals; Glucose; Goals; Gout; Guidelines; Heart Diseases; Hospitalization; Hypersensitivity; Immunology; Inflammatory Arthritis; Internal Medicine; K-Series Research Career Programs; Losartan; Manuscripts; Massachusetts; Medical Informatics; Medicine; Mendelian randomization; Mentors; Mentorship; Methodology; Methods; Modeling; Morbidity - disease rate; New York; Outcome; Outcome Measure; Outcomes Research; Patient Outcomes Assessments; Patient-Focused Outcomes; Patients; Pattern; Peer Review; Pharmaceutical Preparations; Pharmacoepidemiology; Phenotype; Physicians; Premature Mortality; Prevalence; Probability; Public Health Schools; Randomized, Controlled Trials; Recommendation; Registries; Research; Research Personnel; Residencies; Rheumatology; Risk; Risk Factors; Serum; Sodium; Time; Training; Training Activity; United States National Institutes of Health; Universities; Urate; active comparator; burden of illness; cardiometabolic risk; cardiometabolism; cohort; comorbidity; comparative effectiveness; comparative effectiveness study; data centers; data registry; effectiveness research; evidence base; experience; hypertension treatment; illness perceptions; improved; improved outcome; inhibitor; instructor; medical schools; mortality; patient oriented; patient safety; personalized care; prevent; prospective; response; skill acquisition; symporter; treatment guidelines; trend

Candidate: Chio Yokose, MD, MSc is an Instructor in Medicine at Harvard Medical School (HMS) and an Assistant in Medicine in the Division of Rheumatology, Allergy, and Immunology at Massachusetts General Hospital (MGH). After graduating Brown University magna cum laude with her BA in Biology and East Asian Studies, she received her MD from Northwestern University. She completed her internal medicine residency at New York University and her rheumatology fellowship at MGH. She also received her MSc in Epidemiology from the Harvard T.H. Chan School of Public Health. Dr. Yokose conducts patient-centered research focused on gout and its cardiometabolic comorbidities under the mentorship of Hyon Choi, MD, DrPH. Her research has resulted in 17 peer-reviewed original manuscripts (eight as first-author). Her goal is to become an independent investigator and leader in personalized, patient-centered gout research. Mentorship, Training Activities, and Environment: Dr. Yokose will conduct the proposed project at MGH under the mentorship of Hyon Choi, MD, DrPH and co-mentorship of David W. Bates, MD, MSc and Maria Edelen, PhD. Dr. Choi is a world-renowned, NIH-funded physician investigator with expertise in advanced epidemiologic methodologies and risk factors for incident gout. Dr. Bates is a preeminent expert on leveraging medical informatics to conduct patient safety, quality, and clinical effectiveness research. Dr. Edelen has extensive expertise in the development, implementation, analysis, and interpretation of patient-reported outcomes measures (PROMs). Drs. Choi, Bates, and Edelen all have extensive experience mentoring trainees and junior faculty, including multiple prior K awardees. Dr. Yokose will also benefit from the specific expertise of her key collaborators, including pharmacoepidemiology methods and latent class analysis. Under the guidance of her mentorship team, she will acquire skills in new research areas including comparative effectiveness research, research using real-world data, and patient-centered outcomes research using biomarkers and PROMs. Research: The morbidity and mortality burden of gout and its cardiometabolic comorbidities continues to rise. These trends highlight the limitations of our current gout care model in which gout and comorbidities are managed independently. The central goal of this research is to examine the gout benefits of pleiotropic cardiometabolic medications and identify a framework for the personalized integration of gout and comorbidity care to synergistically address gout and comorbidities and ultimately improve outcomes for patients with gout. To achieve this, Dr. Yokose will conduct rigorous comparative effectiveness research examining the serum urate- lowering potential of common cardiometabolic medications (Aim 1) and determine comorbidity phenotypes of incident gout and their relations with serum urate change (key causal precursor to gout) and PROMs related to gout care barriers (Aim 2). By completing this proposal and training plan, Dr. Yokose will gain critical experience to become an independent clinical researcher and leader in personalized, patient-oriented gout research.

候选人：Chio Yokose，医学博士，理学硕士，是哈佛医学院（HMS）的医学讲师， 马萨诸塞州总医院风湿病学、过敏和免疫学分部医学助理 医院（MGH）。布朗大学毕业后，她以优异成绩获得生物学和东亚文学学士学位 她在西北大学获得医学博士学位。她完成了她的内科住院医师在 纽约大学和她在麻省总医院的风湿学奖学金。她还获得了流行病学硕士学位， 哈佛大学陈氏公共卫生学院。Yokose博士以患者为中心进行痛风研究 在Hyon Choi，MD，DrPH的指导下，她的研究结果是 在17个同行评审的原始手稿（八个作为第一作者）。她的目标是成为一个独立的 个性化、以患者为中心痛风研究的研究者和领导者。 导师、培训活动和环境：横濑博士将在MGH主持拟议的项目 在Hyon Choi，MD，DrPH和大卫W.贝茨，医学博士，理学硕士和玛丽亚Edelen， PhD. Choi博士是一位世界知名的NIH资助的医生研究员，在先进的流行病学方面具有专业知识。 方法和风险因素的事件痛风。贝茨医生是利用医疗资源的杰出专家 开展患者安全性、质量和临床有效性研究的信息学。Edelen医生有广泛的 开发、实施、分析和解释患者报告结局的专业知识 措施（PROM）。蔡博士，贝茨和Edelen都有丰富的经验指导学员和初级 教师，包括多个先前的K获奖者。横濑博士还将受益于她的关键的具体专业知识， 合作者，包括药物流行病学方法和潜在类分析。在她的指导下 导师团队，她将获得新的研究领域的技能，包括比较有效性研究， 使用真实世界数据的研究，以及使用生物标志物和PROM的以患者为中心的结果研究。 研究：痛风及其心脏代谢合并症的发病率和死亡率持续上升。 这些趋势突出了我们目前痛风护理模式的局限性，其中痛风和合并症是 独立管理。这项研究的中心目标是检查多效性的痛风好处， 心脏代谢药物，并确定痛风和合并症的个性化整合框架 护理协同解决痛风和合并症，并最终改善痛风患者的预后。 为了实现这一目标，横濑博士将进行严格的比较有效性研究，检查血清尿酸盐- 降低常见心脏代谢药物的潜力（目的1），并确定 偶发痛风及其与血清尿酸盐变化（痛风的关键原因前体）和与 痛风护理障碍（目标2）。通过完成这份建议书和培训计划，横濑博士将获得重要的经验 成为一个独立的临床研究人员和领导者在个性化，以病人为导向的痛风研究。

项目成果

Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: A comparative effectiveness analysis.

使用钠-葡萄糖协同转运蛋白 2 型抑制剂与磺酰脲类药物治疗的痛风患者的血清尿酸变化：比较有效性分析。

• DOI: 10.1016/j.semarthrit.2024.152441
• 发表时间: 2024
• 期刊: Seminars in arthritis and rheumatism
• 影响因子: 5
• 作者: Yokose,Chio;Challener,Greg;Jiang,Bohang;Zhou,Baijun;McCormick,Natalie;Tanikella,Sruthi;Panchot,KilaMeiQin;Kohler,MinnaJ;Yinh,Janeth;Zhang,Yuqing;Bates,DavidW;Januzzi,JamesL;Sise,Meghan;Wexler,Deborah;Choi,HyonK
• 通讯作者: Choi,HyonK